Patents by Inventor Changill Ban
Changill Ban has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117442Abstract: Methods and apparatuses are disclosed for detecting a presence of a mismatched pair in an oligonucleotide duplex that is attached to a solid substrate using an atomic force microscope. In particular, methods and apparatuses of the invention allow qualitative and quantitative analysis of the presence of a mismatched pair in a sample of oligonucleotide duplex using an atomic force microscope comprising an AFM cantilever that includes a DNA mismatch repair protein. Methods and apparatuses of the invention allow detection of gene mutation without a need for amplification, labeling, or modification of the sample. Such apparatuses and methods can be used in a wide variety of clinical diagnostic applications including detection and/or analysis of biomarkers related to, but not limited to, cancer, trauma, sepsis, aseptic inflammation, myocardial infarction, stroke, transplantation, diabetes, sickle cell disease, as well as other clinical conditions.Type: ApplicationFiled: October 19, 2023Publication date: April 11, 2024Applicant: Postech Research and Business Development Foundation (POSTECH)Inventors: Joon Won Park, Sourav Mishra, Changill Ban
-
Patent number: 11634717Abstract: The present invention relates to a DNA aptamer binding specifically to tuberculosis specific antigen 7.7 kDa (TB7.7), a biosensor for diagnosis of tuberculosis, comprising the same, and a method for providing information for diagnosis of tuberculosis. The present inventors found that not only does a DNA aptamer according to the present invention have specific binding potential to TB7.7 protein, but also the binding affinity is excellent. When used, the DNA aptamer of the present invention can be thus expected to exhibit greater stability than a conventional ELISA method using an antibody. Hence, the aptamer is expected to find useful applications in the development of compositions for tuberculosis diagnosis, biosensors for tuberculosis diagnosis, and information providing methods for tuberculosis diagnosis.Type: GrantFiled: September 19, 2018Date of Patent: April 25, 2023Assignee: MD APTUS INC.Inventors: Yoon-Keun Kim, Changill Ban, Chulhun Chang
-
Patent number: 11619633Abstract: The present invention relates to a DNA aptamer binding specifically to early secretory antigenic target 6 kDa (ESAT6), a biosensor for diagnosis of tuberculosis, comprising the same, and a method for providing information for diagnosis of tuberculosis. The present inventors found that not only does a DNA aptamer according to the present invention have specific binding potential to ESAT6 protein, but also the binding affinity is excellent. When used, the DNA aptamer of the present invention can be thus expected to exhibit greater stability than a conventional ELISA method using an antibody. Hence, the aptamer is expected to find useful applications in the development of compositions for tuberculosis diagnosis, biosensors for tuberculosis diagnosis, and information providing methods for tuberculosis diagnosis.Type: GrantFiled: September 19, 2018Date of Patent: April 4, 2023Assignee: MD APTUS INC.Inventors: Yoon-Keun Kim, Changill Ban, Chulhun Chang
-
Patent number: 11193173Abstract: The present invention relates to vesicles derived from bacteria of the genus Propionibacterium and a use thereof. It was experimentally confirmed that the production of vesicles derived from bacteria of the genus Propionibacterium was increased in the body by a high-fat diet rather than a high-carbohydrate diet; the vesicles were significantly reduced in the blood of patients with cancers, such as breast cancer and liver cancer, inflammation diseases, such as asthma and atopic dermatitis, and metabolic diseases, such as diabetes and liver cirrhosis, compared with normal persons; and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, inhibited the apoptosis of keratinocytes, and increased the expression of an androgen receptor in the body.Type: GrantFiled: June 29, 2017Date of Patent: December 7, 2021Inventors: Yoon-Keun Kim, Changill Ban, Jinseong Jeon
-
Patent number: 11028396Abstract: The present invention relates to: a DNA aptamer specifically binding to culture filtrate 10 kDa (CFP10); a biosensor for diagnosing tuberculosis, comprising the same: and an information providing method for diagnosing tuberculosis. The present applicants have ascertained that the DNA aptamer, according to the present invention, has the ability to specifically bind to a CFP10 protein and that the binding strength thereof is strong. When the DNA aptamer of the present invention is used, excellent stability superior to that of ELISA methods using existing antibodies can be expected, and thus it is expected that the aptamer can be effectively used in the development of a composition for diagnosing tuberculosis, a biosensor for diagnosing tuberculosis, an information providing method for diagnosing tuberculosis, and the like.Type: GrantFiled: September 19, 2018Date of Patent: June 8, 2021Inventors: Yoon-Keun Kim, Changill Ban, Chulhun Chang
-
Publication number: 20200407722Abstract: The present invention relates to a DNA aptamer binding specifically to tuberculosis specific antigen 7.7 kDa (TB7.7), a biosensor for diagnosis of tuberculosis, comprising the same, and a method for providing information for diagnosis of tuberculosis. The present inventors found that not only does a DNA aptamer according to the present invention have specific binding potential to TB7.7 protein, but also the binding affinity is excellent. When used, the DNA aptamer of the present invention can be thus expected to exhibit greater stability than a conventional ELISA method using an antibody. Hence, the aptamer is expected to find useful applications in the development of compositions for tuberculosis diagnosis, biosensors for tuberculosis diagnosis, and information providing methods for tuberculosis diagnosis.Type: ApplicationFiled: September 19, 2018Publication date: December 31, 2020Inventors: Yoon-Keun Kim, Changill Ban, Chulhun Chang
-
Publication number: 20200340992Abstract: The present invention relates to a DNA aptamer binding specifically to early secretory antigenic target 6 kDa (ESAT6), a biosensor for diagnosis of tuberculosis, comprising the same, and a method for providing information for diagnosis of tuberculosis. The present inventors found that not only does a DNA aptamer according to the present invention have specific binding potential to ESAT6 protein, but also the binding affinity is excellent. When used, the DNA aptamer of the present invention can be thus expected to exhibit greater stability than a conventional ELISA method using an antibody. Hence, the aptamer is expected to find useful applications in the development of compositions for tuberculosis diagnosis, biosensors for tuberculosis diagnosis, and information providing methods for tuberculosis diagnosis.Type: ApplicationFiled: September 19, 2018Publication date: October 29, 2020Inventors: Yoon-Keun Kim, Changill Ban, Chulhun Chang
-
Publication number: 20200325475Abstract: The present invention relates to: a DNA aptamer specifically binding to culture filtrate 10 kDa (CFP10); a biosensor for diagnosing tuberculosis, comprising the same: and an information providing method for diagnosing tuberculosis. The present applicants have ascertained that the DNA aptamer, according to the present invention, has the ability to specifically bind to a CFP10 protein and that the binding strength thereof is strong. When the DNA aptamer of the present invention is used, excellent stability superior to that of ELISA methods using existing antibodies can be expected, and thus it is expected that the aptamer can be effectively used in the development of a composition for diagnosing tuberculosis, a biosensor for diagnosing tuberculosis, an information providing method for diagnosing tuberculosis, and the like.Type: ApplicationFiled: September 19, 2018Publication date: October 15, 2020Inventors: Yoon-Keun Kim, Changill Ban, Chulhun Chang
-
Publication number: 20190345561Abstract: The present invention relates to vesicles derived from bacteria of the genus Propionibacterium and a use thereof. It was experimentally confirmed that the production of vesicles derived from bacteria of the genus Propionibacterium was increased in the body by a high-fat diet rather than a high-carbohydrate diet; the vesicles were significantly reduced in the blood of patients with cancers, such as breast cancer and liver cancer, inflammation diseases, such as asthma and atopic dermatitis, and metabolic diseases, such as diabetes and liver cirrhosis, compared with normal persons; and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, inhibited the apoptosis of keratinocytes, and increased the expression of an androgen receptor in the body.Type: ApplicationFiled: June 29, 2017Publication date: November 14, 2019Inventors: Yoon-Keun KIM, Changill BAN, Jinseong JEON
-
Patent number: 9429575Abstract: The present invention relates to a DNA aptamer specifically binding to EN2 (Engrailed-2), a biosensor for diagnosing prostate cancer having the same, and a method of diagnosing prostate cancer. A strong binding force and excellent specificity of the DNA aptamer of the present invention and the biosensor using the same with respect to EN2 proteins were identified. A detection specificity problem of a prostate-specific antigen (PSA) test used for prostate cancer diagnosis of the related art was addressed. Therefore, the present invention is expected to be beneficially used for early diagnosis of prostate cancer more effectively and increase diagnostic accuracy.Type: GrantFiled: November 5, 2015Date of Patent: August 30, 2016Assignee: Postech Academy-Industry FoundationInventors: Changill Ban, Yoon-Keun Kim, Hunho Jo, Seonghwan Lee, Hyung Jun Youn
-
Publication number: 20160187342Abstract: The present invention relates to a DNA aptamer specifically binding to EN2 (Engrailed-2), a biosensor for diagnosing prostate cancer having the same, and a method of diagnosing prostate cancer. A strong binding force and excellent specificity of the DNA aptamer of the present invention and the biosensor using the same with respect to EN2 proteins were identified. A detection specificity problem of a prostate-specific antigen (PSA) test used for prostate cancer diagnosis of the related art was addressed. Therefore, the present invention is expected to be beneficially used for early diagnosis of prostate cancer more effectively and increase diagnostic accuracy.Type: ApplicationFiled: November 5, 2015Publication date: June 30, 2016Inventors: Changill Ban, Yoon-Keun Kim, Hunho Jo, Seonghwan Lee, Hyung Jun Youn
-
Patent number: 8541561Abstract: Disclosed herein are a DNA aptamer specifically binding to pLDH (Plasmodium Lactate Dehydrogenase), a composition for the diagnosis of malaria, comprising the same, and a diagnostic kit for malaria using the same. Superior in specificity and stability to antibodies which are conventionally used to diagnose malaria, the DNA aptamers specifically binding to pLDH (Plasmodium Lactate Dehydrogenase) in accordance with the present invention can be developed into biosensors which determine pLDH levels with high sensitivity and accuracy, greatly contributing to the diagnostic accuracy of malaria.Type: GrantFiled: January 20, 2012Date of Patent: September 24, 2013Assignee: Postech Academy-Industry FoundationInventors: Changill Ban, Weejeong Jeon, Seonghwan Lee
-
Patent number: 8404448Abstract: Disclosed are a DNA aptamer specifically binding to human cardiac troponin I, and a composition and a diagnostic kit for the diagnosis of acute cardiovascular diseases, comprising the same. Being superior in specificity and stability to antibodies which are conventionally used to diagnose acute cardiovascular diseases, the DNA aptamers specifically binding to human cardiac troponin I can be developed into biosensors which determine human cardiac troponin I levels with high sensitivity and accuracy, greatly contributing to the diagnosis in an early stage of acute cardiovascular diseases. It is expected to lots of help for increase of diagnostic accuracy.Type: GrantFiled: January 20, 2012Date of Patent: March 26, 2013Assignee: Postech Academy-Industry FoundationInventors: Changill Ban, Kyung-Mi Song, Weejeong Jeon
-
Publication number: 20120316325Abstract: Disclosed herein are a DNA aptamer specifically binding to pLDH (Plasmodium Lactate Dehydrogenase), a composition for the diagnosis of malaria, comprising the same, and a diagnostic kit for malaria using the same. Superior in specificity and stability to antibodies which are conventionally used to diagnose malaria, the DNA aptamers specifically binding to pLDH (Plasmodium Lactate Dehydrogenase) in accordance with the present invention can be developed into biosensors which determine pLDH levels with high sensitivity and accuracy, greatly contributing to the diagnostic accuracy of malaria.Type: ApplicationFiled: January 20, 2012Publication date: December 13, 2012Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Changill BAN, Weejeong JEON, Seonghwan LEE
-
Publication number: 20120316326Abstract: Disclosed are a DNA aptamer specifically binding to human cardiac troponin I, and a composition and a diagnostic kit for the diagnosis of acute cardiovascular diseases, comprising the same. Being superior in specificity and stability to antibodies which are conventionally used to diagnose acute cardiovascular diseases, the DNA aptamers specifically binding to human cardiac troponin I can be developed into biosensors which determine human cardiac troponin I levels with high sensitivity and accuracy, greatly contributing to the diagnosis in an early stage of acute cardiovascular diseases. It is expected to lots of help for increase of diagnostic accuracy.Type: ApplicationFiled: January 20, 2012Publication date: December 13, 2012Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Changill BAN, Kyung-Mi SONG, Weejeong JEON